Paul Stoffels, Johnson & Johnson

Paul Stoffels, Johnson & Johnson ($JNJ)
2012 Pay Package: $7.34 million
2011 Pay Package: N/A (Stoffels became chief scientific officer in October 2012)
2012 Compensation: $825,385 in salary; $1.93 million in stock awards; $1.02 million in option awards; $2.3 million in incentive pay; $1.10 million in pension growth and deferred compensation; $161,466 in other compensation

Johnson & Johnson's Janssen has achieved major successes recently, including the tuberculosis drug Sirturo, which gained FDA approval at the end of 2012. It is the first drug to treat multi-drug resistant tuberculosis, a growing problem, and the first novel therapy approved for TB in 40 years. The pharma company has suffered some setbacks, too. The Alzheimer's drug bapineuzumab, which J&J and Pfizer were developing together, failed spectacularly in a late-stage trial, prompting J&J to slash 130 jobs and rethink its strategy for the disease. But with the FDA's approval of the diabetes-fighting SGLT2 inhibitor Invokana (canagliflozin) in March 2013, the company may have another blockbuster on its hands. And the company continues to ink major R&D deals, including the recent $1 billion buyout of Aragon Pharmaceuticals and its promising new therapy for prostate cancer. 

Many analysts, though, have begun to get restive, looking for more advances to propel future gains.

A physician by training, Paul Stoffels became the head of development for infectious diseases at Janssen Research Foundation in Beerse, Belgium, in 1991 and became CEO of Tibotec-Virco, a biopharma focused on viral diseases, in 1997. Johnson & Johnson bought that company in 2002, and Stoffels took responsibility for the unit. Since 2009, he has served as global head of Johnson & Johnson Pharmaceutical Research & Development.

For more:
Special Report: Paul Stoffels - The 25 most influential people in biopharma today - 2013
In revamped early-stage drive, J&J's Stoffels lets his biotech flag fly
J&J's pharma chairman lands 'more deals' in Boston innovation push
J&J wins first FDA approval for new class of diabetes drug

-- Emily Mullin

Paul Stoffels, Johnson & Johnson

Suggested Articles

Eli Lilly is closing down its U.K.-based Erl Wood neuroscience in Surrey, leading to cuts and relocations.

After being hailed as a near mystic when it came to stock picks, Britain’s once great oak has been cut down to a sapling as Neil Woodford gets the ax.

The series A round sets Abalos up to generate anti-tumoral virus strains and take them toward testing in humans.